Mattern Pharmaceuticals AG, Urigen deal

Mattern granted URGP exclusive, worldwide rights to develop and commercialize Nasobol intranasal testosterone to treat male hypogonadism. Next year, URGP plans to begin additional Phase II testing. Ma...